Strømsnes Torbjørn Austveg, Kaugerud Hagen Truls Jørgen, Ouyang Menglu, Wang Xia, Chen Chen, Rygg Silje-Emilie, Hewson David, Lenthall Rob, McConachie Norman, Izzath Wazim, Bath Philip M, Dhillon Permesh Singh, Podlasek Anna, England Timothy, Sprigg Nikola, Robinson Thompson G, Advani Rajiv, Ihle-Hansen Hege, Sandset Else Charlotte, Krishnan Kailash
Department of Neurosurgery, Oslo University hospital, Norway.
Stroke Unit Department of Neurology, Oslo University hospital, Norway.
Eur Stroke J. 2022 Jun;7(2):99-116. doi: 10.1177/23969873221078136. Epub 2022 Mar 2.
Low blood pressure (BP) in acute ischaemic stroke (AIS) is associated with poor functional outcome, death, or severe disability. Increasing BP might benefit patients with post-stroke hypotension including those with potentially salvageable ischaemic penumbra. This updated systematic review considers the present evidence regarding the use of vasopressors in AIS.
We searched the Cochrane Database of Systematic Reviews, MEDLINE, EMBASE and trial databases using a structured search strategy. We examined reference lists of relevant publications for additional studies examining BP elevation in AIS.
We included 27 studies involving 1886 patients. Nine studies assessed increasing BP during acute reperfusion therapy (intravenous thrombolysis, mechanical thrombectomy, intra-arterial thrombolysis or combined). Eighteen studies tested BP elevation alone. Phenylephrine was the most commonly used agent to increase BP (n = 16 studies), followed by norepinephrine (n = 6), epinephrine (n = 3) and dopamine (n = 2). Because of small patient numbers and study heterogeneity, a meta-analysis was not possible. Overall, BP elevation was feasible in patients with fluctuating or worsening neurological symptoms, large vessel occlusion with labile BP, sustained post-stroke hypotension and ineligible for intravenous thrombolysis or after acute reperfusion therapy. The effects on functional outcomes were largely unknown and close monitoring is advised if such intervention is undertaken.
Although theoretical arguments support increasing BP to improve cerebral blood flow and sustain the ischaemic penumbra in selected AIS patients, the data are limited and results largely inconclusive. Large, randomised controlled trials are needed to identify the optimal BP target, agent, duration of treatment and effects on clinical outcomes.
急性缺血性卒中(AIS)患者的低血压与功能预后不良、死亡或严重残疾相关。升高血压可能使包括那些具有潜在可挽救缺血半暗带的卒中后低血压患者受益。本更新的系统评价考虑了目前关于在AIS中使用血管升压药的证据。
我们使用结构化检索策略检索了Cochrane系统评价数据库、MEDLINE、EMBASE和试验数据库。我们检查了相关出版物的参考文献列表,以寻找其他研究AIS中血压升高情况的研究。
我们纳入了27项研究,涉及1886例患者。9项研究评估了急性再灌注治疗(静脉溶栓、机械取栓、动脉内溶栓或联合治疗)期间升高血压的情况。18项研究单独测试了血压升高情况。去氧肾上腺素是最常用的升高血压药物(16项研究),其次是去甲肾上腺素(6项)、肾上腺素(3项)和多巴胺(2项)。由于患者数量少且研究存在异质性,无法进行荟萃分析。总体而言,在神经症状波动或恶化、大血管闭塞且血压不稳定、卒中后持续性低血压以及不符合静脉溶栓条件或急性再灌注治疗后的患者中,升高血压是可行的。对功能预后的影响大多未知,如果进行此类干预,建议密切监测。
尽管理论上支持升高血压以改善脑血流并维持选定AIS患者的缺血半暗带,但数据有限且结果大多尚无定论。需要进行大型随机对照试验,以确定最佳血压目标、药物、治疗持续时间以及对临床结局的影响。